European approval lets Novo Nordisk market Frehemgo to prevent or reduce bleeding in hemophilia A, and Saudi Arabia has approved it too. The U.S. review is still pending, but the approvals give the drug access to new markets.
The European approval gives Novo Nordisk another place to offer a hemophilia A treatment. Its flexible dosing may suit patients who prefer fewer injections. Saudi Arabia has also approved the drug, but the U.S. decision is still pending.
Follow Novo Nordisk (NVO) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for NVO